In a randomized phase III clinical trial, the anti-PD-L1 antibody atezolizumab combined with docetaxel was effective in controlling disease progression in NSCLC patients compared to chemotherapy alone. The gene discussed is CD274; the disease is non-small cell lung carcinoma.